This innovative use of Cellia’s core technology has the potential to improve the quality and reliability of bone marrow aspiration procedures.
Cellia Science, has been awarded a Phase I Small Business Technology Transfer (STTR) grant by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), a division of the National Institutes of Health (NIH). This grant will fund the development of an innovative point-of-care instrument that aims to assess the adequacy of bone marrow aspirates, a critical component in the diagnosis, staging, and monitoring of hematologic conditions and cancers.
Bone marrow aspirates are instrumental in providing crucial insights into various medical conditions, such as leukemia, aplastic anemia, sickle cell disease, and metastasis of solid tumors. However, the success rate of these aspirations can be hindered by factors like operator technique, hemodilution, or underlying pathology, leading to failure rates up to 50%. Cellia Science's groundbreaking project aims to revolutionize the quality and reliability of bone marrow aspiration procedures by introducing an instrument that assesses the adequacy that can be used during the procedure.
The principal investigator of this grant is Dr. Paco Robles, Professor at Georgia Institute of Technology and Chief Scientific Officer at Cellia Science. Dr. Robles shared his excitement about the project: "My team, along with Dr. Aumann and Dr. Aljudi, have collaborated to explore the potential of deep UV microscopy in the field of hematology. We are thrilled to harness the capabilities of UV imaging for bone marrow aspirate adequacy screening, leveraging its unique attributes to tackle critical clinical challenges."
Dr. Kelly Mabry, the CEO of Cellia Science, expressed the company's enthusiasm for the collaborative effort: "We are excited about the opportunity to work closely with our academic collaborators to bring this groundbreaking technology to the clinic. We are thankful for the support from NIBIB as we work towards advancing patient care."
The successful implementation of Cellia Science's automated point-of-care instrument holds the potential to significantly enhance the success rate of bone marrow aspiration procedures, leading to improved patient care and outcomes. The company's dedication to innovation and partnership with leading research institutions underscores its commitment to redefining the landscape of modern healthcare.
About Cellia Science
Cellia Science is committed to developing innovative diagnostic solutions that transform healthcare. The company was founded in 2021 to address unmet needs in hematology with their label-free deep-UV imaging technology. To learn more, visit celliasci.com
About VIC Tech
VIC Tech is a technology venture development firm that creates innovative new companies with world-changing science- and engineering-based technologies. VIC carefully selects and licenses technologies from universities and research institutions around the world, then partners technology entrepreneurs with VIC’s team of business and technology experts and allocates seed capital through the nationally comprised VIC Investor Network. VIC provides its portfolio companies with senior management expertise, extensive knowledge of technology startups, and proven processes to execute business strategies, including legal, financial, operations, marketing, capital acquisition, and technology management. For more information, please visit victech.com